23:59 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest combinations of bispecific small molecules targeting fluorescein and CAIX, PSMA or FOLR1 plus anti-fluorescein CAR T cells could help treat triple-negative breast cancer (TNBC). The bispecific adapter molecules consist...
19:50 , Jul 6, 2018 |  BC Extra  |  Preclinical News

New uses for marketed drugs in tough-to-treat indications

Two studies in Science Translational Medicine suggest three generics could be repurposed for difficult to treat indications. A paper from University of Edinburgh researchers showed that endothelial cell-targeted drugs simvastatin and perindopril could help treat...
20:47 , Nov 10, 2017 |  BC Week In Review  |  Financial News

Telix raises A$50M in Australian IPO

On Nov. 9, Telix Pharmaceuticals Ltd. (ASX:TLX) raised A$50 million ($38.3 million) through the sale of 77 million shares at A$0.65 in an IPO underwritten by Taylor Collison and Wilsons Corporate Finance. The price values...
22:18 , Nov 9, 2017 |  BC Extra  |  Financial News

Telix raises A$50M in Australian IPO

Telix Pharmaceuticals Ltd. (ASX:TLX) raised A$50 million ($38.3 million) through the sale of 77 million shares at A$0.65 in an IPO underwritten by Taylor Collison and Wilsons Corporate Finance. The price values the company at...
19:33 , Jan 20, 2017 |  BC Week In Review  |  Company News

Wilex, Telix deal

Wilex granted newco Telix exclusive, worldwide rights to develop and commercialize Redectane (124-iodine-girentuximab). The radiolabeled WX-G250 antibody has completed one Phase III trial as a diagnostic imaging agent for clear cell renal cell carcinoma (RCC)....
07:00 , Aug 20, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Co-crystal structures of small molecules with carbonic anhydrase IX (CAIX) mimetic and CAII for the design of CAIX-specific compounds

Drug platforms CAIX CAII SignalChem Lifesciences Corp. SLC-0111 Bayer AG Seattle Genetics Inc. anti-CA9 ADC BAY 79-4620 carbonic anhydrase IX (CAIX) University of Florida...
07:00 , May 14, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Carbonic anhydrase I (CAI); CAII; CAIX; CAXII

Ophthalmic disease INDICATION: Glaucoma In vitro and rabbit studies suggest carbonic anhydrase-inhibiting dendrimers could help treat glaucoma. Chemical synthesis and in vitro testing of poly(amidoamine) (PAMAM)-based dendrimers linked to multiple carbonic anhydrase-inhibiting benzenesulfonamide functional groups...
07:00 , Apr 27, 2015 |  BioCentury  |  Product Development

CAR window

MaxCyte Inc. is collaborating with the Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University to develop transiently expressed chimeric antigen receptor T cell therapies that may allow better control over the cells' therapeutic...
08:00 , Feb 26, 2015 |  BC Innovations  |  Tools & Techniques

The Power of Two

The goal of chemical libraries is to contain enough molecules that even targets with uncommon binding sites can find the rare compound that binds with high affinity. Rather than synthesizing hundreds of thousands of molecules,...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

SLC-0111: Phase Ia started

SignalChem began an open-label, dose-escalation, Canadian Phase Ia trial to evaluate once-daily SLC-0111 in 28-day cycles in up to 30 patients. SignalChem Lifesciences Corp. , Richmond, Beta.C.   Product: SLC-0111   Business: Cancer   Molecular...